Eton Pharmaceuticals, Inc. (ETON)
Largest Insider Buys in Sector
ETON Stock Price History Chart
ETON Stock Performance
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Insider Activity of Eton Pharmaceuticals, Inc.
Over the last 12 months, insiders at Eton Pharmaceuticals, Inc. have bought $1.02M and sold $0 worth of Eton Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eton Pharmaceuticals, Inc. have bought $983,754 and sold $20.77M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Opaleye Management Inc. (10 percent owner) — $6.11M.
The last purchase of 10,000 shares for transaction amount of $79,814 was made by Opaleye Management Inc. (10 percent owner) on 2024‑10‑23.
List of Insider Buy and Sell Transactions, Eton Pharmaceuticals, Inc.
| 2024-10-23 | 10 percent owner | 10,000 0.0782% | $7.98 | $79,814 | +48.09% | |||
| 2024-10-08 | 10 percent owner | 33,970 0.2339% | $7.03 | $238,782 | +44.26% | |||
| 2024-10-07 | 10 percent owner | 11,248 0.0796% | $7.22 | $81,250 | +45.21% | |||
| 2024-10-04 | 10 percent owner | 16,852 0.1118% | $6.77 | $114,105 | +50.71% | |||
| 2024-09-11 | 10 percent owner | 50,000 0.2326% | $4.75 | $237,500 | +81.63% | |||
| 2024-09-10 | 10 percent owner | 57,500 0.2619% | $4.65 | $267,375 | +81.69% | |||
| 2022-09-22 | Chief Executive Officer | 10,000 0.0382% | $2.10 | $21,042 | +61.29% | |||
| 2021-11-17 | Sale | 10 percent owner | 25,000 0.1% | $4.67 | $116,713 | -31.32% | ||
| 2021-11-16 | Sale | 10 percent owner | 12,438 0.0495% | $4.86 | $60,472 | -34.12% | ||
| 2021-11-15 | Sale | 10 percent owner | 3,000 0.0112% | $4.80 | $14,405 | -37.28% | ||
| 2021-11-08 | Sale | 10 percent owner | 52,661 0.2268% | $6.10 | $321,285 | -41.81% | ||
| 2021-11-05 | Sale | 10 percent owner | 167,701 0.6665% | $6.30 | $1.06M | -46.74% | ||
| 2021-11-04 | Sale | 10 percent owner | 85,700 0.3409% | $6.44 | $551,651 | -47.20% | ||
| 2021-11-03 | Sale | 10 percent owner | 116,500 0.4622% | $6.53 | $760,850 | -47.32% | ||
| 2021-10-12 | Sale | 10 percent owner | 87,307 0.3414% | $5.06 | $441,485 | -28.85% | ||
| 2021-10-11 | Sale | 10 percent owner | 34,101 0.136% | $5.01 | $170,716 | -26.61% | ||
| 2021-10-08 | Sale | 10 percent owner | 43,692 0.1737% | $5.00 | $218,469 | -26.45% | ||
| 2021-08-20 | President & CEO | 10,000 0.0388% | $4.32 | $43,200 | -12.02% | |||
| 2021-08-20 | CFO, Treasurer & Secretary | 5,000 0.0199% | $4.43 | $22,150 | -12.02% | |||
| 2021-08-06 | Sale | 10 percent owner | 345,000 1.358% | $5.84 | $2.01M | -32.88% |
Insider Historical Profitability
| Opaleye Management Inc. | 10 percent owner | 2770000 10.3999% | $14.39 | 7 | 17 | <0.0001% |
| HARROW HEALTH, INC. | 10 percent owner | 1982000 7.4414% | $14.39 | 0 | 1 | |
| BRYNJELSEN SEAN | Chief Executive Officer | 1040000 3.9047% | $14.39 | 7 | 0 | <0.0001% |
| CASAMENTO CHARLES J | director | 71920 0.27% | $14.39 | 2 | 0 | +1.97% |
| RIEDEL NORBERT G | director | 59745 0.2243% | $14.39 | 1 | 0 | +7.11% |
| MAIER PAUL V | director | 59745 0.2243% | $14.39 | 1 | 0 | +7.11% |
| Troutman William Wilson | CFO, Treasurer & Secretary | 23027 0.0865% | $14.39 | 2 | 0 | <0.0001% |
| BAUM MARK L | director | 10000 0.0375% | $14.39 | 1 | 0 | +7.11% |